Speaking with @Bloomberg TV from Amgen's newest manufacturing facility in West Greenwich, Rhode Island, Amgen CEO Bob Bradway said the plant has set a new standard for efficiency and environmental sustainability and will enable Amgen to meet growing demand for its medicines, many of which treat serious and widespread chronic diseases. He warned, though, that recent U.S. drug price control legislation threatens to discourage biopharmaceutical innovation just when it is most needed. Bradway spoke on September 14 with "Bloomberg: Market Close" co-anchors Caroline Hyde and Taylor Riggs. Bradway remarked that the new Rhode Island facility expands Amgen's ability to manufacture protein-based medicines "at an improved cost and improved efficiency in a shorter timeframe than any other facility in the world." He emphasized the plant's environmental sustainability, noting that "we have been able to shrink the footprint by some 75 percent and dramatically decrease the amount of energy and water we consume and the amount of waste we produce." Read more at Amgen.com